Novo Nordisk A/SNVONYSE
Loading
EBITDA as a percentage of revenue
3Y CAGR
+3.7%/yr
vs -1.5%/yr prior
5Y CAGR
+0.7%/yr
Consistent
Acceleration
+5.3pp
Accelerating
Percentile
P93
Near historical high
vs 5Y Ago
1x
Modest growth
Streak
1 yr
Consecutive growthStable
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 48.43% | +2.4% |
| 2024 | 47.31% | -4.2% |
| 2023 | 49.35% | +13.7% |
| 2022 | 43.40% | -6.6% |
| 2021 | 46.44% | -0.5% |
| 2020 | 46.69% | +4.7% |
| 2019 | 44.61% | -3.4% |
| 2018 | 46.16% | -0.7% |
| 2017 | 46.51% | +1.8% |
| 2016 | 45.68% | - |